## Elizabeth P Henske

## List of Publications by Citations

Source: https://exaly.com/author-pdf/1426859/elizabeth-p-henske-publications-by-citations.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9,694 66 56 23 h-index g-index citations papers 66 11,385 11.5 4.95 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
56	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , <b>2016</b> , 12, 1-222	10.2	3838
55	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-	5 <b>46</b> .2	2783
54	The somatic genomic landscape of chromophobe renal cell carcinoma. <i>Cancer Cell</i> , <b>2014</b> , 26, 319-330	24.3	521
53	Unjamming and cell shape in the asthmatic airway´epithelium. <i>Nature Materials</i> , <b>2015</b> , 14, 1040-8	27	300
52	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , <b>2018</b> , 23, 313-326.e5	10.6	295
51	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. <i>Cancer Cell</i> , <b>2017</b> , 31, 820-	8 <b>32.</b> 93	286
50	Tuberous sclerosis complex. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16035	51.1	265
49	Lymphangioleiomyomatosis - a wolf in sheeple clothing. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 3807	7=11569	205
48	Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. <i>Lancet, The</i> , <b>2003</b> , 361, 1348-9	40	173
47	Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. <i>Journal of Experimental Medicine</i> , <b>2014</b> , 211, 2249-63	16.6	134
46	Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 186, 1210-2	10.2	119
45	Aggressive variants of chromophobe renal cell carcinoma. <i>Cancer</i> , <b>1996</b> , 78, 1756-61	6.4	91
44	Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. <i>PLoS Genetics</i> , <b>2016</b> , 12, e1006242	6	62
43	New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex. <i>Journal of Pathology</i> , <b>2017</b> , 241, 219-225	9.4	55
42	Folliculin regulates cell-cell adhesion, AMPK, and mTORC1 in a cell-type-specific manner in lung-derived cells. <i>Physiological Reports</i> , <b>2014</b> , 2, e12107	2.6	40
41	Renal disease in tuberous sclerosis complex: pathogenesis and therapy. <i>Nature Reviews Nephrology</i> , <b>2018</b> , 14, 704-716	14.9	39
40	Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial. <i>Chest</i> , <b>2017</b> , 151, 1302-1310	5.3	36

## (2021-2016)

39	Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. <i>Pediatric Neurology</i> , <b>2016</b> , 60, 1-12	2.9	34
38	Mechanisms of pulmonary cyst pathogenesis in Birt-Hogg-Dube syndrome: The stretch hypothesis. <i>Seminars in Cell and Developmental Biology</i> , <b>2016</b> , 52, 47-52	7.5	33
37	p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis. <i>Cancer Research</i> , <b>2017</b> , 77, 3255-3267	10.1	32
36	Tumour predisposition and cancer syndromes as models to study gene-environment interactions. <i>Nature Reviews Cancer</i> , <b>2020</b> , 20, 533-549	31.3	32
35	The Genetics of Pneumothorax. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 199, 1344-1357	10.2	27
34	TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	26
33	Human Pluripotent Stem Cell-Derived -Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis. <i>Cancer Research</i> , <b>2017</b> , 77, 5491-5502	10.1	22
32	Familial pneumothorax: towards precision medicine. <i>Thorax</i> , <b>2018</b> , 73, 270-276	7.3	19
31	Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2015</b> , 53, 33-41	5.7	18
30	Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2(-) Tumor Related to Lymphangioleiomyomatosis. <i>American Journal of Pathology</i> , <b>2016</b> , 186, 1825-1836	5.8	16
29	Emerging biomarkers of lymphangioleiomyomatosis. <i>Expert Review of Respiratory Medicine</i> , <b>2018</b> , 12, 95-102	3.8	15
28	Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop. <i>American Journal of Physiology - Renal Physiology</i> , <b>2014</b> , 306, F279-83	4.3	13
27	Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. <i>Oncotarget</i> , <b>2017</b> , 8, 64714-64727	3.3	13
26	Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation. <i>Cancer Research</i> , <b>2017</b> , 77, 1492-1502	10.1	12
25	Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion. <i>Journal of Experimental Medicine</i> , <b>2019</b> , 216, 2635-2652	16.6	10
24	Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. <i>Oncotarget</i> , <b>2017</b> , 8, 17628-17642	3.3	10
23	Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis. <i>Chest</i> , <b>2018</b> , 154, 1070-1082	5.3	10
22	TSC2 regulates lysosome biogenesis via a non-canonical RAGC and TFEB-dependent mechanism.  Nature Communications, <b>2021</b> , 12, 4245	17.4	9

21	Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future Directions. <i>Chest</i> , <b>2019</b> , 156, 1062-1067	5.3	8
20	A genome-wide association study implicates in lymphangioleiomyomatosis pathogenesis. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	8
19	Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor [[RAR]] <i>Oncogene</i> , <b>2019</b> , 38, 7367-7383	9.2	7
18	Renal Manifestations of Tuberous Sclerosis Complex <b>2010</b> , 311-325		7
17	Lysosomal regulation of cholesterol homeostasis in tuberous sclerosis complex is mediated via NPC1 and LDL-R. <i>Oncotarget</i> , <b>2017</b> , 8, 38099-38112	3.3	7
16	MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61. <i>Oncogene</i> , <b>2021</b> , 40, 112-126	9.2	6
15	Lymphangioleiomyomatosis and Pulmonary Disease in TSC <b>2010</b> , 345-368		4
14	Mesenchymal folliculin is required for alveolar development: implications for cystic lung disease in Birt-Hogg-Dubßyndrome. <i>Thorax</i> , <b>2020</b> , 75, 486-493	7.3	4
13	Kidney intercalated cells and the transcription factor FOXi1 drive cystogenesis in tuberous sclerosis complex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	4
12	Targeted deletion of Tsc1 causes fatal cardiomyocyte hyperplasia independently of afterload. <i>Cardiovascular Pathology</i> , <b>2015</b> , 24, 80-93	3.8	3
11	Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	3
10	The Codon 72 Polymorphism Contributes to TSC Tumorigenesis through the Notch-Nodal Axis. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 1639-1651	6.6	2
9	Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis-associated lymphangioleiomyomatosis. <i>Orphanet Journal of Rare Diseases</i> , <b>2019</b> , 14, 72	4.2	2
8	Getting to the finish line with mTORC1-targeted therapy. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 1970-2	15.9	2
7	Renal Cell Carcinoma in Tuberous Sclerosis Complex. <i>Genes</i> , <b>2021</b> , 12,	4.2	2
6	Seventh BHD international symposium: recent scientific and clinical advancement <i>Oncotarget</i> , <b>2022</b> , 13, 173-181	3.3	1
5	Generalised mosaicism for mutation in isolated lymphangioleiomyomatosis. <i>European Respiratory Journal</i> , <b>2019</b> , 54,	13.6	1
4	Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex. <i>Cancer Research</i> , <b>2021</b> , 81, 2086-2100	10.1	1

## LIST OF PUBLICATIONS

3	Modeling tuberous sclerosis with organoids <i>Science</i> , <b>2022</b> , 375, 382-383	33.3	Ο
2	Chromophobe renal cell carcinoma: New genetic and metabolic insights. <i>Urologic Oncology:</i> Seminars and Original Investigations, <b>2020</b> , 38, 678-681	2.8	O
1	The TSC Complex-mTORC1 Axis: From Lysosomes to Stress Granules and Back. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 751892	5.7	O